Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June May 26, 2026
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults May 21, 2026
Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026 March 4, 2026
Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026 February 24, 2026
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults February 20, 2026
